
-
Kenya's economy faces climate change risks: World Bank
-
Stellantis pausing some Canada, Mexico production over Trump auto tariffs
-
Rising odds asteroid that briefly threatened Earth will hit Moon
-
Is the Switch 2 worth the price? Reviews are mixed
-
Countries eye trade talks as Trump tariff blitz roils markets
-
AI could impact 40 percent of jobs worldwide: UN
-
US trade partners eye talks after Trump tariff blitz
-
Dollar, stocks sink as gold hits high on Trump tariffs
-
Trump tariff blitz sparks retaliation threats, economic fears
-
Lessons and liquids: buried alive in Myanmar's earthquake
-
Nintendo Switch 2 sparks excitement despite high price
-
Sri Lanka's crackdown on dogs for India PM's visit sparks protest
-
China vows 'countermeasures' to sweeping new US tariffs
-
Trump jolts allies, foes and markets with tariff blitz
-
How Trump's 'liberation day' tariffs will impact China
-
Europe hits out at Trump tariffs, keeps door open for talks
-
Australia sweats through hottest 12 months on record: official data
-
South African artist champions hyenas in 'eco-queer' quest
-
Taiwan says US tariffs 'highly unreasonable'
-
Trump escalates trade war with sweeping global tariffs
-
China says opposes new US tariffs, vows 'countermeasures'
-
Quake-hit Myanmar's junta chief to head to Bangkok summit
-
New Spielberg, Nolan films teased at CinemaCon
-
Shiny and deadly, unexploded munitions a threat to Gaza children
-
Stocks tank, havens rally as Trump tariffs fan trade war
-
Financial markets tumble after Trump tariff announcement
-
Europe riled, but plans cool-headed response to Trump's tariffs
-
'Shenmue' voted most influential video game ever in UK poll
-
Revealed: Why monkeys are better at yodelling than humans
-
Key details on Trump's market-shaking tariffs
-
US business groups voice dismay at Trump's new tariffs
-
Trump sparks trade war with sweeping global tariffs
-
US stocks end up, but volatility ahead after latest Trump tariffs
-
Boeing chief reports progress to Senate panel after 'serious missteps'
-
Is Musk's political career descending to Earth?
-
On Mexico-US border, Trump's 'Liberation Day' brings fears for future
-
Tesla sales slump as pressure piles on Musk
-
Amazon makes last-minute bid for TikTok: report
-
Tesla first quarter sales sink amid anger over Musk politics
-
World's tiniest pacemaker is smaller than grain of rice
-
Nintendo says Switch 2 console to be launched on June 5
-
Certain foreign firms must 'self-certify' with Trump diversity rules: US embassies
-
Nigerian president sacks board of state oil company
-
Heathrow 'warned about power supply' days before shutdown
-
Epstein accuser Virginia Giuffre 'stable' after car crash
-
Swedish insurer drops $160 mn Tesla stake over labour rights
-
Stock markets mixed as uncertainty rules ahead of Trump tariffs
-
Warner showcases 'Superman' reboot, new DiCaprio film
-
Asian markets edge up but uncertainty rules ahead of Trump tariffs
-
UK imposes online entry permit on European visitors

Moderna sues Pfizer, BioNTech for Covid-19 vaccine patent infringement
Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.
The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease.
"Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement.
"This groundbreaking technology was critical to the development of Moderna's own mRNA Covid-19 vaccine, Spikevax. Pfizer and BioNTech copied this technology, without Moderna's permission, to make Comirnaty," Moderna added.
US-based Pfizer said it has not received the lawsuit and declined to speak further, while Germany's BioNTech did not immediately reply to a request for comment.
The mRNA technology used in the Moderna and Pfizer-BioNTech shots differs from that in traditional vaccines, which rely on injecting weakened or dead forms of a virus to allow the immune system to recognize it and build antibodies.
Instead, mRNA vaccines deliver instructions to cells to build a harmless piece of the spike protein found on the surface of the virus that causes Covid-19.
After creating this spike protein, cells can recognize and fight the real virus, hailed as a major advancement in development of vaccines.
- Key tool against deadly pandemic -
The shots have repeatedly been the subject of inaccurate claims that they are dangerous, but health authorities say they are both safe and effective.
The lawsuits -- to be filed in filed Friday both in US district court in Massachusetts, and in regional court in Dusseldorf, Germany -- are not seeking the removal of the rival vaccine or an injunction on future sales.
Moderna said it had begun building up the technology in 2010 and patented work on coronaviruses in 2015 and 2016, which allowed for rollout of its shots in "record time" after the pandemic struck.
The virus has killed at least 6.48 million people worldwide since 2020 and made nearly 600 million ill, according to a Johns Hopkins University tracker.
In addition to death and suffering, the disease has led to a re-shaping of life ranging from a change in norms on working from home to a scrambling of supply chains and workforces.
Moderna said it pledged in October 2020 not to enforce its Covid-19-related patents while the pandemic continued, but less than two years later changed that stance as the fight shifted gears.
"Moderna expected companies such as Pfizer and BioNTech to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets," it said.
"Pfizer and BioNTech have failed to do so," the firm added.
These types of lawsuits are not unheard of in the pharmaceutical industry, where patents can be worth billions of dollars, and can take years to resolve.
T.Morelli--CPN